NPR Shots interviews some of the psychiatrists who feel that the fast-acting drug ketamine is a “revolution” in depression treatment.
“I think it’s highly probable that we’ll see some version of one of these treatments being approved in the relatively near future,” Dr. Gerard Sanacora tells NPR. “In my mind it is the most exciting development in mood disorder treatment in the last 50 years.”
NPR notes that, “Sanacora has done consulting work for both Naurex and Johnson & Johnson,” and that, “Johnson & Johnson included esketamine on a list of drugs with potential annual sales of more than $1 billion.”
Depression Treatments Inspired By Club Drug Move Ahead In Tests (NPR Shots, May 28, 2015)